Yohannes Belay*, Bamlaku Enawgaw , Feyissa Challa , Meron Sileshi, Amha Gebremedhin and Ketsela Yirdaw
Background Tumor lysis syndrome is one of a catastrophic cŽnÄ?ÅÆ?ÅŽn of mƵůÆ?ÅÆ?ůÄ? metabolic derangements that occur in bulk and rapidly dividing cancer. It is most commonly associated with hematological malignancies and results in ÆÅÅnÅĨÅcÄ?nÆ? mortality and morbidity. The aim of this study was to determine the incidence and factors Æ?rÄ?Ä?ÅcÆ?ÅnÅ laboratory tumor lysis syndrome in Æ?Ä?Æ?ÅÄ?nÆ?Æ with hematological malignancies. Methods A Æ?rŽÆÆ?Ä?cÆ?ÅvÄ? cohort study was conducted on 49 Æ?Ä?Æ?ÅÄ?nÆ?Æ diagnosed with hematological malignancies at Tikur Anbessa specialized hospital from September 2017 to April 2018. Data and blood sample were collected Ä?ĨÆ?Ä?r ÅÄ?Æ?Æ?ÅnÅ wrÅÆ?Æ?Ä?n informed consent from the Æ?Ä?Æ?ÅÄ?nÆ?ÆÍ? Laboratory tumor lysis syndrome was assessed based on the Cairo and Bishop Ä?Ä?ĨÅnÅÆ?ÅŽn criteria using daily measured laboratory values of uric acid, potassium, phosphate and calcium. A regression analysis was used to assess the ÆÆ?Ä?Æ?ÅÆÆ?ÅcÄ?ů Ä?ÆÆŽcÅÄ?Æ?ÅŽn between incidence and factors Æ?rÄ?Ä?ÅcÆ?ÅnÅ laboratory tumor lysis syndrome. Results The incidence of laboratory tumor lysis syndrome (LTLS) was 30.6% with 4.1% spontaneous and 26.5% new onset of LTLS. White blood cell count ≥ 25x109/L (AOR: 5.47, 95% CI: 1.11-26.96), lactate dehydrogenase level ≥2 Æ?ÅmÄ?Æ upper limit normal (AOR: 8.97, 95 % CI: 1.73-46.45)and age ≥ 60 years (AOR: 8.75, 95 % CI: 1.27-60.56) were independent factors Æ?rÄ?Ä?ÅcÆ?ÅnÅ LTLS. Conclusion More than one-fourth of Æ?Ä?Æ?Ä?nÆ?Æ with hematological malignancies developed LTLS. Increased baseline white blood cell count, lactate dehydrogenase level and age were the main factors Æ?rÄ?Ä?ÅcÆ?ÅnÅ LTLS. Keywords: Tumor lysis syndrome; Hematological malignancy; Incidence; White blood cell count.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi